Regulation (EU) 2019/6 overhauled the European Union’s legal framework for veterinary medicinal products, establishing a modernized system to harmonize the internal market and strengthen efforts against antimicrobial resistance. The legislation, which officially repealed the older Directive 2001/82/EC, took effect to address regulatory fragmentation that previously created barriers to trade and inconsistent health protections across member states.
Harmonizing the Internal Market for Veterinary Drugs
Before the implementation of Regulation (EU) 2019/6, divergent transposition of Directive 2001/82/EC across European Union member states led to varying levels of public and animal health protection. The current framework introduces uniform rules designed to streamline procedures, reduce administrative burdens for developers and regulators, and stimulate innovation within the veterinary sector.
To receive a marketing authorization under the updated rules, all veterinary medicinal products must undergo a rigorous scientific evaluation of their quality, safety, and efficacy. Information regarding centrally authorized products and their evaluation procedures is maintained in the Union Register of Medicinal Products. Furthermore, regulatory and scientific guidelines compiled within “The Rules Governing Medicinal Products in the European Union,” known as EudraLex, help facilitate the uniform application of these laws across all member states.
Combating Antimicrobial Resistance and Boosting Product Availability
A primary driver behind the updated European legislation is strengthening EU action to fight antimicrobial resistance (AMR).
To ensure smooth implementation, the European Commission is tasked with adopting supplementary delegated and implementing acts.
Frequently Asked Questions
What are veterinary medicinal products?
Veterinary medicinal products, also referred to as veterinary medicines or drugs, are substances or combinations of substances presented for treating or preventing disease in animals, or for restoring, correcting, or modifying physiological functions.
Why was Directive 2001/82/EC replaced?
Directive 2001/82/EC was replaced by Regulation (EU) 2019/6 because inconsistent national transpositions created barriers to the internal market and uneven levels of animal and public health protection across the European Union.
How does the current regulation address antimicrobial resistance?
Related reading
- Guadeloupe Wins Bronze in Women’s Nation Cup at Central American and Caribbean Games
- Naples Celebrates Centenary with Spectacular Midnight Flare Show
- Buy Pharmaceutical Products Safely Only in Authorized Pharmacies (archyde.com)
- Big Ten, SEC join to support Protect College Sports Act, breathing new life into landmark legislation (newsylist.com)